Nauticus Robotics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nauticus Robotics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $11.43M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $8.59M | Mar 28, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.27M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.81M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $6.61M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $11.43M | Apr 10, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($40.83M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($134.91M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($50.69M) | Apr 15, 2025 |
| FY2022 | Dec 31, 2022 | ($8.22M) | Mar 28, 2023 |
| FY2022 | Sep 30, 2022 | ($13.18M) | Mar 28, 2023 |
| FY2022 | Jun 30, 2022 | ($3.36M) | Mar 28, 2023 |
| FY2022 | Mar 31, 2022 | ($3.50M) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | ($11.23M) | Mar 28, 2023 |
| FY2022 | Sep 30, 2021 | ($1.30M) | Mar 28, 2023 |
| FY2022 | Jun 30, 2021 | ($1.07M) | Mar 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.73M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($23.31M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($55.10M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($18.38M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($6.52M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.0K) | Mar 29, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $82.9K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.40M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $2.38M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $3.53M | Mar 28, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.00M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($24.35M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($21.69M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($37.27M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($7.50M) | Mar 28, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.61M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $22.69M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $26.15M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $52.60M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $25.17M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $25.0K | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.59M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $43.08M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $67.94M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $52.58M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | $31.78M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $1.0K | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.02M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($20.40M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | ($41.79M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $27.8K | Apr 15, 2025 |
| FY2022 | Sep 30, 2022 | $6.27M | Mar 28, 2023 |
| FY2022 | Jun 30, 2022 | ($13.08M) | Mar 28, 2023 |
| FY2022 | Mar 31, 2022 | ($9.92M) | Mar 28, 2023 |
| FY2023 | Dec 31, 2021 | ($6.61M) | Apr 10, 2024 |
| FY2022 | Sep 30, 2021 | ($5.00M) | Mar 28, 2023 |
| FY2022 | Jun 30, 2021 | ($3.81M) | Mar 28, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.60M | Apr 15, 2026 |
| FY2025 | Mar 19, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Apr 15, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($323.52M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($253.70M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($118.79M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($68.11M) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | ($39.84M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.0K) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.02M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.19M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $753.4K | Apr 15, 2025 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.51M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $28.94M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $31.60M | Apr 15, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (10) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (330) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (44) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 29, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (10) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (330) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (44) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 28.81M | Apr 15, 2026 |
| FY2025 | Sep 5, 2025 | 4.75M | Apr 15, 2026 |
| FY2025 | Sep 4, 2025 | 42.76M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 1.08M | Apr 15, 2026 |
| FY2025 | Jul 22, 2024 | 4.17M | Apr 15, 2026 |
| FY2025 | Jul 21, 2024 | 150.11M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 1.39M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 47.25M | Apr 10, 2024 |
| FY2022 | Dec 31, 2021 | 9.67M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 4.31M | Mar 29, 2022 |